Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.55%
- Poor long term growth as Net Sales has grown by an annual rate of 2.88% and Operating profit at 17.41% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
With a fall in Net Sales of -24.4%, the company declared Very Negative results in Mar 25
3
With ROE of 3.24%, it has a very expensive valuation with a 3.59 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,199 Million (Mid Cap)
111.00
NA
0.00%
0.84
3.24%
3.59
Revenue and Profits:
Net Sales:
786 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.05%
0%
6.05%
6 Months
-2.98%
0%
-2.98%
1 Year
-24.0%
0%
-24.0%
2 Years
-30.91%
0%
-30.91%
3 Years
-40.93%
0%
-40.93%
4 Years
-47.47%
0%
-47.47%
5 Years
23.91%
0%
23.91%
New Journey Health Technology Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.88%
EBIT Growth (5y)
17.41%
EBIT to Interest (avg)
1.26
Debt to EBITDA (avg)
3.79
Net Debt to Equity (avg)
0.74
Sales to Capital Employed (avg)
0.90
Tax Ratio
24.21%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.55%
ROE (avg)
3.44%
Valuation key factors
Factor
Value
P/E Ratio
111
Industry P/E
Price to Book Value
3.59
EV to EBIT
37.10
EV to EBITDA
17.68
EV to Capital Employed
2.40
EV to Sales
2.51
PEG Ratio
2.85
Dividend Yield
NA
ROCE (Latest)
6.48%
ROE (Latest)
3.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
786.50
1,040.30
-24.40%
Operating Profit (PBDIT) excl Other Income
88.10
122.70
-28.20%
Interest
31.90
32.10
-0.62%
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-17.50
38.20
-145.81%
Operating Profit Margin (Excl OI)
36.50%
66.20%
-2.97%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -24.40% vs 26.51% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -145.81% vs -0.52% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,774.30
3,892.10
-3.03%
Operating Profit (PBDIT) excl Other Income
519.70
401.70
29.38%
Interest
137.70
132.10
4.24%
Exceptional Items
3.00
14.00
-78.57%
Consolidate Net Profit
120.30
39.90
201.50%
Operating Profit Margin (Excl OI)
72.90%
34.40%
3.85%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -3.03% vs 23.88% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 201.50% vs -75.80% in Dec 2023
About New Journey Health Technology Group Co., Ltd. 
New Journey Health Technology Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






